ClinicalTrials.gg
RecruitingNCT07165717Updated Sep 10, 2025

A Real World Study of Respiratory Critical Disease.

An observational study in ARDS (Acute Respiratory Distress Syndrome) and Real World Study, sponsored by Ming Zhong. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Ming Zhong · Observational

How we know

From the registry’s dates

  • Started Mar 2019; still recruiting 7 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Acute Lung Injury with a site in China — 20 open to participants now, 20 under way, 1 of them phase 3. Acute Lung Injury · China.

Planned enrollment
5th of 28
500 · median 103
Started
2019
with 1 other
Observational
28 of 59
10 open now
Primary completion
2025-07
later than 1 of 19 live
Registered
46th of 59
by date
Lead sponsor
2 of 59
Ming Zhong

Among the 59 studies in Acute Lung Injury with a site in China, this one is the 5th largest by planned enrollment of the 28 observational ones that give a count, is one of 2 that started in 2019, is one of 28 observational ones, reaches primary completion later than 1 of the 19 other live ones, and was the 46th registered.

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

Browse Acute Lung Injury studies →

Open to participants now

20 of the 59 studies in Acute Lung Injury with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Acute Lung Injury with a site in China, or all of them as a file.
02

Study summary

Acute Respiratory Distress Syndrome (ARDS) is a form of acute diffuse lung injury caused by various etiologies, which rapidly progresses to acute respiratory failure. It is characterized by a sudden onset and severe clinical course. Globally, ARDS affects approximately 3 million individuals each year, accounting for about 10% of admissions to intensive care units (ICUs). Due to the lack of specific pharmacological therapies, mechanical ventilation remains the mainstay of treatment. Therefore, identifying and analyzing prognostic factors for ARDS patients is of great significance for improving patient outcomes and reducing the incidence of poor prognosis.

03

Conditions studied

  • ARDS (Acute Respiratory Distress Syndrome)
  • Real World Study

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients identified as high risk for ARDS after ICU admission.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with underlying diseases associated with high risk of ARDS, including but not limited to: sepsis, pneumonia, multiple trauma, pulmonary contusion, inhalation injury, massive blood transfusion, other high-risk conditions, or other factors causing excessive respiratory drive.
  • Patients meeting the inclusion criteria for a high-risk ARDS population.
  • Patients (or legal representatives) who have provided a signed and dated form.

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years.
  • infection.
  • Known immunodeficiency disorders (e.g., leukemia, common variable immunodeficiency, etc.).
  • History of solid organ or bone marrow transplantation.
  • Receiving treatment with G-CSF or GM-CSF.
  • Patients with a decision to withdraw from active treatment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No

Interventions

  • OtherNo Intervention: Observational Cohort

    Obsercational study

06

What researchers measure

Primary outcomes

  1. Mortality

    Clinical observation

    Time frame: Day 28 after ARDS diagnosis

  2. Mortality

    Clinical observation

    Time frame: Day 60 after ARDS diagnosis

Secondary outcomes

  1. Chest CT Scan

    Chest CT imaging

    Time frame: Monitored daily

  2. Complete Blood Count

    Blood sampling and laboratory testing

    Time frame: Monitored daily

  3. Serial Arterial Blood Gas Monitoring

    Arterial blood gas collection

    Time frame: Monitored daily after enrollment

  4. Fluid Input and Output Balance

    Clinical nursing records

    Time frame: Whenever fluid input or output occurs

  5. Mechanical Ventilation Monitoring

    Automatically recorded by ventilator

    Time frame: Every second after intubation

07

Study locations

1 of 1 sites recruiting
  • Fudan University, Zhong Shan Hospital
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Jul 2025, 76 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2025
First posted
Sep 10, 2025
StartActual
Mar 1, 2019
Primary completionActual
Jul 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07165717
Lead sponsor
Ming Zhong
Responsible party
Ming Zhong (PI, Shanghai Zhongshan Hospital) — Sponsor-investigator
First posted
Sep 10, 2025
Start date
Mar 1, 2019
Primary completion
Jul 31, 2025
Completion
Dec 31, 2025 (estimated)
Last update
Sep 10, 2025

Study contacts

Yuxian Wang, Doctor
Contact
wang.yuxian@zs-hospital.sh.cn
86-13482359545

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion